Gerontology and geriatrics, a worldwide expansion in 2009: Data from the IAGG World Meeting Paris 2009, July 5–9th B. VellasB. Forette Editorial 09 May 2009 Pages: 292 - 292
Metabolic response to a ketogenic breakfast in the healthy elderly E. FreemantleM. VandalS. C. Cunnane JNHA: Nutrition 09 May 2009 Pages: 293 - 298
Impact of food aid on food variety and dietary diversity of an elderly community in Sharpeville, South Africa W. H. Oldewage-TheronR. Kruger Impact of Food Aid on Food Variety and Dietary Diversity 09 May 2009 Pages: 300 - 308
Unawareness of weight and height - the effect on self-reported prevalence of overweight in a population-based study E. RamosC. LopesH. Barros Awareness of Weight and Height 09 May 2009 Pages: 310 - 314
The association of thyroid stimulating hormone levels with cognitive function and depressed mood: The Rancho Bernardo study D. Kritz-SilversteinS. T. SchultzE. Barrett-Connor JNHA: Clinical Neurosciences 09 May 2009 Pages: 317 - 321
Sleep disorders and their impacts on healthy, dependent, and frail older adults Valérie CochenC. ArbusB. Vellas Sleep Disorders and Their Impacts on Healthy, Dependent, and Frail Older Adults 09 May 2009 Pages: 322 - 329
Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer’s disease M. W. Weiner Editorial 09 May 2009 Pages: 332 - 333
Biomarkers for Alzheimer’s disease trials — biomarkers for what? A discussion paper S. LovestoneM. Thambisetty Biomarkers for Alzheimer’s Disease Trials — Biomarkers for What? A Discussion Paper 09 May 2009 Pages: 334 - 336
Interpreting biomarker data in therapeutic trials P. S. Aisen JNHA: Clinical Trials and Aging 09 May 2009 Pages: 337 - 338
Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies? C. Sampaio JNHA: Clinical Trials and Aging 09 May 2009 Pages: 339 - 340
How can we recognize “disease modification” effects? E. R. Siemers JNHA: Clinical Trials and Aging 09 May 2009 Pages: 341 - 343
Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment P. J. Visser Use of Biomarkers to Select the Target Population for Clinical Trials 09 May 2009 Pages: 344 - 345
Molecular imaging markers in clinical trials in Alzheimer’s disease A. Nordberg Molecular Imaging Markers in Clinical Trials in Alzheimer’s Disease 09 May 2009 Pages: 346 - 347
Neuro-imaging: Structural and functional imaging G. B. Frisoni Neuro-Imaging: Structural and Functional Imaging 09 May 2009 Pages: 348 - 349
Structural imaging markers for therapeutic trials in Alzheimer’s disease N. C. FoxJ. Kennedy Structural Imaging Markers for Therapeutic Trials in Alzheimer’s Disease 09 May 2009 Pages: 350 - 352
Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data W. M. Van Der FlierP. Scheltens JNHA: Clinical Trials and Aging 09 May 2009 Pages: 353 - 355
Interest of the new criteria for drug trials in AD B. Dubois Interest of the New Criteria for Drug Trials in AD 09 May 2009 Pages: 356 - 357
Use of CSF biomarkers in Alzheimer’s disease clinical trials K. BlennowH. Zetterberg Use of CSF Biomarkers in Alzheimer’s Disease Clinical Trials 09 May 2009 Pages: 358 - 361
What we have learned from the myriad trials S. B. HendrixG. K. Wilcock What We Have Learned from the Myriad Trials 09 May 2009 Pages: 362 - 364
What we have learned from the xaliproden Sanofi-aventis trials P. DouilletJ. -M. Orgogozo JNHA: Clinical Trials and Aging 09 May 2009 Pages: 365 - 366
Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy C. WischikR. Staff JNHA: Clinical Trials and Aging 09 May 2009 Pages: 367 - 369
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience D. SaumierP. S. AisenJ. Sampalis The Alzhemed™ (Tramiprosate) Experience 09 May 2009 Pages: 370 - 372
Enrichment of MCI and early Alzheimer’s disease treatment trials using neurochemical & imaging candidate biomarkers H. HampelK. Broich JNHA: Clinical Trials and Aging 09 May 2009 Pages: 373 - 375
The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES) C. C. Gispen-De WiedM. KritsidimaA. J. A. Elferink The Validity of Biomarkers as Surrogate Endpoints in Alzheimer’s Disease 09 May 2009 Pages: 376 - 387
Defining frailty — the holy grail of geriatric medicine S. Conroy JNHA: Geriatric Science 09 May 2009 Pages: 389 - 389
Frailty: Defining and measuring of a concept R. E. Pel-LittelM. J. SchuurmansH. J. J. Verhaar Frailty: Defining and Measuring of a Concept 09 May 2009 Pages: 390 - 394